Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects

British Journal of Clinical Pharmacology

Volumn 78, Issue 5, 2014, Pages 1035-1042

  Sidharta, Patricia N ^a   Van Giersbergen, Paul L M ^a   Wolzt, Michael ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Drug drug interaction; Endothelin receptor antagonist; Healthy subjects; Macitentan; Pharmacokinetics; Sildenafil

Indexed keywords

DRUG METABOLITE; MACITENTAN; SILDENAFIL; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; HUMAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; BLOOD; DRUG ADMINISTRATION; DRUG INTERACTION; ENZYME SPECIFICITY; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENDOTHELIN RECEPTOR ANTAGONISTS; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; PYRIMIDINES; SILDENAFIL CITRATE; SUBSTRATE SPECIFICITY; SULFONAMIDES; YOUNG ADULT;

EID: 84918802150     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12447     Document Type: Article

References (49)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
2. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
3. Lederman MM, Sereni D, Simonneau G, Voelkel NF. Pulmonary arterial hypertension and its association with HIV infection: an overview. AIDS 2008; 22: (Suppl. 3): S1-6.
4. Abenhaim L, Humbert M. Pulmonary hypertension related to drugs and toxins. Curr Opin Cardiol 1999; 14: 437-41.
5. Boutet K, Montani D, Jais X, Yaici A, Sitbon O, Simonneau G, Humbert M. Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2008; 2: 249-65.
6. Reinhart K, Salerno E, White CM. Pulmonary arterial hypertension: an overview of current pharmacologic treatment. Conn Med 2008; 72: 531-4.
7. Osman MN, Dunlap ME. Management of heart failure with pulmonary hypertension. Curr Cardiol Rep 2005; 7: 196-203.
8. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S-8S.
9. O'Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007; 28: 169-85, ix.
10. Benza RL, Park MH, Keogh A, Girgis RE. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant 2007; 26: 437-46.
11. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-10.
12. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-18.
13. Patel T, McKeage K. Macitentan: first global approval. Drugs 2014; 74: 127-33.
14. Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf 2014; 13: 391-405.
15. Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS ONE 2012; 7: e47662.
16. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327: 736-45.
17. Weiss J, Theile D, Ruppell MA, Speck T, Spalwisz A, Haefeli WE. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol 2013; 701: 168-75.
18. Sidharta PN, Dietrich H, Dingemanse J. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. Clin Drug Investig 2014; 34: 545-52
19. Bruderer S, Aanismaa P, Homery MC, Hausler S, Landskroner K, Sidharta PN, Treiber A, Dingemanse J. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J 2012; 14: 68-78.
20. Summary of Product Characteristics: Opsumit® (macitentan) 10 mg tablets, for oral use. Actelion Registration, Ltd. 2013.
21. Treiber A, Aanismaa P, de Kanter R, Delahaye S, Treher M, Hess P, Sidharta P. Macitentan does not interfere with hepatic bile salt transport. J Pharmacol Exp Ther 2014; 350: 130-43.
22. Atsmon J, Dingemanse J, Shaikevich D, Volokhov I, Sidharta PN. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet 2013; 52: 685-92.
23. Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011; 67: 977-84.
24. Sidharta PN, van Giersbergen PL, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol 2013; 53: 1131-8.
25. Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003; 59: 713-33.
26. Product Information: Revatio® (sildenafil), Pfizer Ltd, August 2008.
27. Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35: 1400-7.
28. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64: 43-50.
29. Prescribing Information: Opsumit® (macitentan) tablets, for oral use. Actelion Pharmaceuticals US, Inc. 2013.
30. Kummer O, Haschke M, Hammann F, Bodmer M, Bruderer S, Regnault Y, Dingemanse J, Krahenbuhl S. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci 2009; 38: 384-8.
31. Hyland R, Roe EG, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001; 51: 239-48.
32. Spence R, Mandagere A, Dufton C, Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol 2008; 48: 1451-9.
33. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005; 1: 429-45.
34. Prescribing Information: Tracleer® (bosentan tablets), Actelion Pharmaceuticals US, Inc. 2012.
35. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.
36. Rubin LJ, Badesch DB, Fleming TR, Galie N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011; 140: 1274-83.
37. Gruenig E, Michelakis E, Vachiery JL, Vizza CD, Meyer FJ, Doelberg M, Bach D, Dingemanse J, Galie N. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009; 49: 1343-52.
38. FDA. Guidance for industry: drug interaction studies-study design, data analysis, implications for dosing and labeling recommendations. Draft Guidance, February, 2012.
39. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
40. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
41. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011; 9: (Suppl. 1): 12-9.
42. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013; 52: 69-82.
43. Product Information: Xarelto® (rivaroxaban) tablets, for oral use. Janssen Pharmaceuticals Inc, 2011.
44. Shader RI, Oesterheld JR. Contraceptive effectiveness: cytochromes and induction. J Clin Psychopharmacol 2000; 20: 119-21.
45. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43: 1089-115.
46. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60: 107-12.
47. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005; 7: 47-56.
48. van Giersbergen PL, Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol 2007; 63: 151-8.
49. Guo S, Ashina M, Olesen J, Birk S. The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects. Cephalalgia 2013; 33: 301-7.